Human embryonic stem cell research has emerged as an important
platform for the understanding and treatment of pediatric diseases.
From its inception, however, it has raised ethical concerns based
not on the use of stem cells themselves but on objections to the source
of the cells—specifically, the destruction of preimplantation human
embryos. Despite differences in public opinion on this issue, a large
majority of the public supports continued research using embryonic
stem cells.
Maintenance of developmental potential for contribution of derivatives of all three germ layers is an important feature of these cells. This ability remains consistent even after clonal derivation or prolonged undifferentiated proliferation, thus pronouncing its accelerated uptake.
In addition, these are capable in expressing high level of alkaline phosphatase, key transcription factors, and telomerase. These factors are found to be of great importance in the maintenance of the inner cellular mass pluripotency.
In 2018, the global Human Embryonic Stem Cell (hESC) market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Human Embryonic Stem Cell (hESC) status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Human Embryonic Stem Cell (hESC) development in United States, Europe and China.
The key players covered in this study
Astellas Institute of Regenerative Medicine (US)
Asterias Biotherapeutics, Inc. (US)
BD Biosciences (US)
Cell Cure Neurosciences Ltd. (Israel)
Cellular Dynamics International (US)
GE Healthcare (UK)
MilliporeSigma (US)
PerkinElmer, Inc. (US)
Reliance Life Sciences Ltd. (India)
Research & Diagnostics Systems, Inc. (US)
SABiosciences Corp. (US)
STEMCELL Technologies, Inc. (Canada)
Stemina Biomarker Discovery, Inc. (US)
Takara Bio, Inc. (Japan)
TATAA Biocenter AB (Sweden)
Thermo Fisher Scientific, Inc. (US)
UK Stem Cell Bank (UK)
ViaCyte, Inc. (US)
Vitrolife AB (Sweden)
Market segment by Type, the product can be split into
Totipotent Stem Cell
Pluripotent Stem Cell
Unipotent Stem Cell
Market segment by Application, split into
Research
Clinical Trials
Others
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Human Embryonic Stem Cell (hESC) status, future forecast, growth opportunity, key market and key players.
To present the Human Embryonic Stem Cell (hESC) development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Human Embryonic Stem Cell (hESC) are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Summary:
Get latest Market Research Reports on Human Embryonic Stem Cell (hESC). Industry analysis & Market Report on Human Embryonic Stem Cell (hESC) is a syndicated market report, published as Global Human Embryonic Stem Cell (hESC) Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Human Embryonic Stem Cell (hESC) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.